News & Updates
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 Excerpt from the Press Release: PRINCETON, NJ, Sept. 18, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic…
Read More
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human dosing now expected third quarter 2025 New preclinical data on ORKA-001 to be presented at EADV in September showing robust preclinical activity including a half-life in NHPs of over 30 days…
Read More Vertex System Designed to Bring the Precision and Control of Direct Surgical Access to Catheter-Based Interventions Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control™, announced today that the first two patients have been treated in SPIRARE I (NCT06571760),…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor…
Read More
-Results highlight ADI-001’s potential as a best-in-class allogeneic cell therapy for autoimmune disease- -Webcast featuring Dr. Blake Aftab with accompanying presentation available on Company website- Excerpt from the Press Release: REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Sept. 13, 2024 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotech company pioneering a new way to activate T cells targeting the Vβ chain of the T cell receptor to select the optimal T cell subsets against cancer, today announced that it has entered into a clinical study collaboration…
Read More
– In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment – – Initial data are at…
Read More
Excerpt from the Press Release: SAN DIEGO, Sept. 12, 2024 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its ERUDITE™ Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia. The ERUDITE study was the second…
Read More
Excerpt from the Press Release: – Preclinical data demonstrate pharmacodynamic activity of KRIYA-586, an investigational gene therapy which encodes for an anti-IGF1R antibody – – Kriya anticipates advancing KRIYA-586 into the clinic in 2025 to evaluate its safety and efficacy in people suffering from TED – Click the button below to read the entire Press…
Read More
The news comes on the heels of SubtleSYNTH receiving FDA clearance of SubtleSYNTH™ for Spine STIRs Excerpt from the Press Release: MENLO PARK, Calif., Sept. 4, 2024 /PRNewswire/ — Subtle Medical, a leader in AI-powered medical imaging solutions, is proud to announce that it has been awarded Phase II funding of its NIH SBIR grant to further develop…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?